Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 310

Results For "HR"

6007 News Found

Zydus acquires UK based LiqMeds Group
News | November 02, 2023

Zydus acquires UK based LiqMeds Group

Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026


Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru
Biotech | October 31, 2023

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution


Indian Health Minister Dr. Mandaviya addresses 76th session of the WHO Regional Committee for South-East Asia
Policy | October 31, 2023

Indian Health Minister Dr. Mandaviya addresses 76th session of the WHO Regional Committee for South-East Asia

India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind


Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India
News | October 31, 2023

Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India

The drug will be marketed by Sun Pharma under the brand name RYTSTAT


Alkem ‘Healthy Lungs' initiative aims to clear the air
News | October 31, 2023

Alkem ‘Healthy Lungs' initiative aims to clear the air

The initiative will focus on advocating for cleaner air


Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
News | October 30, 2023

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr

Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter


Mandaviya inaugurates Rural Health Training Centre (RHTC) Hospital in Najafgarh, Delhi
Healthcare | October 26, 2023

Mandaviya inaugurates Rural Health Training Centre (RHTC) Hospital in Najafgarh, Delhi

RHTC will address a long-standing healthcare access issue for all the local population


Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer
Drug Approval | October 26, 2023

Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients


Venus Remedies earns REO Certification from CII for second consecutive year
News | October 26, 2023

Venus Remedies earns REO Certification from CII for second consecutive year

The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)


Nanoform grant global starmap AI license to AstraZeneca
Digitisation | October 25, 2023

Nanoform grant global starmap AI license to AstraZeneca

Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening